| Literature DB >> 35326761 |
Samuel Cashman-Kadri1,2,3, Patrick Lagüe4,5,6, Ismail Fliss1,2, Lucie Beaulieu1,2,3.
Abstract
The structure-activity relationships and mode of action of synthesized glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-related antimicrobial peptides were investigated. Including the native skipjack tuna GAPDH-related peptide (SJGAP) of 32 amino acid residues (model for the study), 8 different peptide analogs were designed and synthesized to study the impact of net charge, hydrophobicity, amphipathicity, and secondary structure on both antibacterial and antifungal activities. A net positive charge increase, by the substitution of anionic residues or C-terminal amidation, improved the antimicrobial activity of the SJGAP analogs (minimal inhibitory concentrations of 16-64 μg/mL), whereas the alpha helix content, as determined by circular dichroism, did not have a very definite impact. The hydrophobicity of the peptides was also found to be important, especially for the improvement of antifungal activity. Membrane permeabilization assays showed that the active peptides induced significant cytoplasmic membrane permeabilization in the bacteria and yeast tested, but that this permeabilization did not cause leakage of 260 nm-absorbing intracellular material. This points to a mixed mode of action involving both membrane pore formation and targeting of intracellular components. This study is the first to highlight the links between the physicochemical properties, secondary structure, antimicrobial activity, and mechanism of action of antimicrobial peptides from scombrids or homologous to GAPDH.Entities:
Keywords: GAPDH; SJGAP; antimicrobial peptides; membrane permeabilization; structure–activity relationships
Year: 2022 PMID: 35326761 PMCID: PMC8944596 DOI: 10.3390/antibiotics11030297
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Net charges, isoelectric points, molar weights, and GRAVY indexes of the peptide analogs used in this study.
| Peptide Analogs | Sequences | Net Charges | Isoelectric Points | Molar Weights (g/mol) | GRAVY Indexes |
|---|---|---|---|---|---|
| 1 (SJGAP) | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND | +4 | 11.4 | 3436.07 | 0.272 |
| 2 | VKVGINGFGRIG | +2 | 11.4 | 1216.45 | 0.558 |
| 3 | IGRLVTRAAFHG | +2 | 12.1 | 1297.53 | 0.433 |
| 4 | HGKKVEIVAIND | 0 | 7.6 | 1322.53 | −0.225 |
| VKVGINGFGRIGRLVTRAAFHGKKV | +6 | 12.4 | 3334.02 | 0.603 | |
| 6 * | VKVGINGFGRIGRLVTRAAFHGKKV | +8 | 12.5 | 3448.21 | 0.247 |
| 7 * | VKVGINGFGRIGRLVTR | +4 | 11.4 | 3562.21 | 0.459 |
| 8 * | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIN | +5 | 11.9 | 3435.08 | 0.272 |
* Substituted or modified residues are highlighted in bold.
Minimal inhibitory concentrations (MICs) and bactericidal concentrations (MBCs) of peptide analogs against seven bacterial strains.
| Peptide Analogs | Antibacterial Activity (MIC; MBC) (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|
| 1 (SJGAP) | n.a. 1 | ||||||
| 2 | n.a. | ||||||
| 3 | n.a. | ||||||
| 4 | n.a. | ||||||
| 5 | 32; 128 | 32; 64 | 16; n.b.a. 2 | 32; 64 | 32; 128 | 64; n.b.a. | 32; n.b.a. |
| 6 | 64; 64 | 16; 32 | 16; 128 | 64; 128 | 64; n.b.a. | 64; n.b.a. | 32; n.b.a. |
| 7 | n.a. | ||||||
| 8 | 64; 64 | 32; 32 | 64; n.b.a. | 128; n.b.a. | n.a. | n.a. | n.a. |
1 No activity; 2 No bactericidal activity.
MICs and minimal fungicidal concentrations (MFCs) of peptide analogs against six fungal strains.
| Peptide Analogs | Antifungal Activity (MIC; MFC) (μg/mL) | |||||
|---|---|---|---|---|---|---|
| 1 (SJGAP) | n.a. 1 | n.a. | 128; - | n.a. | 128; n.f.a. 2 | n.a. |
| 2 | n.a. | |||||
| 3 | n.a. | |||||
| 4 | n.a. | n.a. | n.a. | n.a. | 64; n.f.a. | n.a. |
| 5 | n.a. | n.a. | 32; n.f.a. | 32; 64 | 64; n.f.a. | n.a. |
| 6 | n.a. | n.a. | 32; n.f.a. | 32; 64 | 64; n.f.a. | n.a. |
| 7 | n.a. | n.a. | 16; n.f.a. | 32; 64 | 64; n.f.a. | n.a. |
| 8 | n.a. | n.a. | 64; n.f.a. | n.a. | 64; n.f.a. | n.a. |
1 No activity; 2 No fungicidal activity.
Figure 1Circular dichroism (CD) spectra of peptide analogs 1–8 in (a) 10 mM phosphate buffer (PB), (b) trifluoroethanol (TFE) 25%, (c) TFE 50% and (d) TFE 75%.
Secondary structure contents of peptide analogs from the CONTIN algorithm analysis of CD spectra.
| Peptide Analogs | Secondary Structure Contents (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PB (10 mM) | TFE 25% | TFE 50% | TFE 75% | |||||||||
| α-Helix | β-Strands | Unrd * | α-Helix | β-Strands | Unrd * | α-Helix | β-Strands | Unrd * | α-Helix | β-Strands | Unrd * | |
| 1 (SJGAP) | 6 | 35 | 37 | 4 | 42 | 33 | 6 | 40 | 32 | 7 | 38 | 33 |
| 2 | 6 | 44 | 35 | 5 | 40 | 33 | 4 | 41 | 34 | 5 | 38 | 35 |
| 3 | 5 | 33 | 39 | 6 | 37 | 35 | 15 | 33 | 30 | 18 | 29 | 31 |
| 4 | 6 | 32 | 39 | 5 | 32 | 37 | 4 | 39 | 35 | 6 | 34 | 33 |
| 5 | 6 | 33 | 39 | 5 | 41 | 32 | 6 | 41 | 32 | 8 | 38 | 32 |
| 6 | 6 | 30 | 41 | 6 | 42 | 31 | 39 | 17 | 24 | 41 | 14 | 28 |
| 7 | 8 | 33 | 36 | 4 | 42 | 33 | 7 | 38 | 33 | 16 | 30 | 33 |
| 8 | 7 | 30 | 40 | 5 | 40 | 34 | 25 | 23 | 31 | 36 | 18 | 26 |
* Unordered (random coils).
Figure 2Secondary structures of (a) analog 1(SJGAP), (b) analog 5, (c) analog 6, and (d) analog 7, as predicted by PSIPRED.
Figure 3SYTO 9 (530 nm) / propidium iodide (PI) (630 nm) absorbance ratios, as obtained with the LIVE/DEAD® BacLight Bacterial Viability kit for (a) E. coli ATCC 11229, (b) M. luteus LMA-272, and (c) R. mucilaginosa 27173. Each value is the average of three independent repetitions, performed in technical triplicates, and error bars represent standard deviations. Values sharing a common letter are not significantly different, according to Tukey HSD test (p ≤ 0.05).
Sequences and research interest of peptide analogs synthesized for this study.
| Peptide Analogs | Sequence | Research Interest/Analog Modification |
|---|---|---|
| 1 (SJGAP) | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND | Native SJGAP; model for this study |
| 2 | VKVGINGFGRIG | N-terminal segment of SJGAP |
| 3 | IGRLVTRAAFHG | Middle segment of SJGAP |
| 4 | HGKKVEIVAIND | C-terminal segment of SJGAP |
| 5 * | VKVGINGFGRIGRLVTRAAFHGKKV | Substitution of anionic residues with neutral alanine residues |
| 6 * | VKVGINGFGRIGRLVTRAAFHGKKV | Substitution of anionic residues with cationic lysine residues (+4 net charge) |
| 7 * | VKVGINGFGRIGRLVTR | Substitution of alanine residues by more hydrophobic leucine residues |
| 8 * | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIN | C-terminal amidation |
* Substituted or modified residues are highlighted in bold.
Identification and description of the bacterial and fungal strains used in this study.
| Genus | Species | Strain | Type | Study Relevance |
|---|---|---|---|---|
|
|
| ATCC 25922 | Gram-negative | Human pathogen; reference strain [ |
|
|
| ATCC 11229 | Gram-negative | Non-pathogenic |
|
|
| ATCC 27853 | Gram-negative | Human pathogen |
|
|
| 69 R3 a | Gram-negative | Fish pathogen |
|
|
| 69 R5 a | Gram-negative | Fish pathogen |
|
|
| LMA-272 b | Gram-positive | Human skin flora; opportunistic pathogen |
|
|
| ATCC 19119 | Gram-positive | Human pathogen |
|
|
| 27 173 c | Yeast | Human pathogen; food spoilage |
|
|
| 27 169 c | Yeast | Food spoilage |
|
|
| LL12_088 d | Yeast | Food spoilage |
|
|
| 3071-13 e | Filamentous fungi | Food spoilage |
|
|
| LMA-722 b | Filamentous fungi | Food spoilage; opportunistic pathogen |
|
| sp. | 5332-9 e | Filamentous fungi | Food spoilage; opportunistic pathogen |
a Strain provided by Professor Steve Charette (Labo Charette, Université Laval, QC, Canada); b strain collection of Professor Steve Labrie (Laboratoire de Microbiologie Alimentaire, Université Laval, QC, Canada); c strain collection of General Mills Yoplait (Boulogne-Billancourt, France); d strain collection of Professor Christian Landry (Université Laval, QC, Canada); e strain collection of Professor Denis Roy (Université Laval, QC, Canada).